Brief: Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints
30/05/2026 13:12
BRIEF-Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints May 30 (Reuters) - Immunome Inc IMNM.O:
IMMUNOME - VAREGACESTAT TREATMENT RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY AND ALL KEY SECONDARY EFFICACY ENDPOINTS
Source text: ID:nBwtqyzva
Further company coverage: IMNM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage